MA71388A - Composés pyrido[4,3-d]pyrimidines - Google Patents

Composés pyrido[4,3-d]pyrimidines

Info

Publication number
MA71388A
MA71388A MA71388A MA71388A MA71388A MA 71388 A MA71388 A MA 71388A MA 71388 A MA71388 A MA 71388A MA 71388 A MA71388 A MA 71388A MA 71388 A MA71388 A MA 71388A
Authority
MA
Morocco
Prior art keywords
pyrido
pyrimidine compounds
pyrimidine
compounds
Prior art date
Application number
MA71388A
Other languages
English (en)
Inventor
Scott Channing Sutton
John Howard Tatlock
Asako Nagata
Simon Paul Planken
Jacob Cole DEFOREST
Jillian Elyse SPANGLER
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of MA71388A publication Critical patent/MA71388A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA71388A 2022-07-05 2023-06-30 Composés pyrido[4,3-d]pyrimidines MA71388A (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263358324P 2022-07-05 2022-07-05
US202263394338P 2022-08-02 2022-08-02
US202263414939P 2022-10-11 2022-10-11
US202363502931P 2023-05-18 2023-05-18
PCT/IB2023/056844 WO2024009191A1 (fr) 2022-07-05 2023-06-30 Composés pyrido[4,3-d]pyrimidines
EP23744558.0A EP4551296A1 (fr) 2022-07-05 2023-06-30 Composés pyrido[4,3-d]pyrimidines

Publications (1)

Publication Number Publication Date
MA71388A true MA71388A (fr) 2025-04-30

Family

ID=87426656

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71388A MA71388A (fr) 2022-07-05 2023-06-30 Composés pyrido[4,3-d]pyrimidines

Country Status (17)

Country Link
EP (1) EP4551296A1 (fr)
JP (1) JP2025525406A (fr)
KR (1) KR20250029954A (fr)
CN (1) CN119585286A (fr)
AU (1) AU2023302139A1 (fr)
CA (1) CA3261000A1 (fr)
CL (1) CL2024003699A1 (fr)
CO (1) CO2024016875A2 (fr)
CR (1) CR20240556A (fr)
DO (1) DOP2024000275A (fr)
IL (1) IL317957A (fr)
MA (1) MA71388A (fr)
MX (1) MX2024015001A (fr)
PE (1) PE20250259A1 (fr)
PY (1) PY2352053A (fr)
TW (2) TWI869913B (fr)
WO (1) WO2024009191A1 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
MD4051678T2 (en) 2019-10-28 2026-07-31 Merck Sharp & Dohme Llc Small molecule inhibitors of the KRAS G12C mutant
WO2021085653A1 (fr) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. Dérivés de 4-aminobut-2-enamide et sels de ces derniers
EP4067343A4 (fr) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. Nouveau composé phénolique ou sel de celui-ci
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
WO2021215544A1 (fr) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Inhibiteurs de protéine kras g12d
WO2022109487A1 (fr) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Inhibiteurs 6,7-dihydro-pyrano[2,3-d]pyrimidine à substitution spirocyclique du mutant kras g12c
US20260200925A1 (en) * 2021-11-24 2026-07-16 Merck Sharp & Dohme Llc Small molecule inhibitors of kras mutated proteins
WO2023172737A1 (fr) 2022-03-11 2023-09-14 Kumquat Biosciences Inc. Composés hétérocycliques et leurs utilisations
AU2023320565A1 (en) 2022-08-05 2025-01-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2024032703A1 (fr) * 2022-08-11 2024-02-15 Beigene, Ltd. Composés hétérocycliques, compositions à base de ceux-ci et procédés de traitement associés
AU2023321005A1 (en) * 2022-08-12 2025-03-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tricyclic compounds and medical use thereof
TW202434606A (zh) * 2022-11-17 2024-09-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合三環類化合物、其製備方法及其在醫藥上的應用
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
WO2024178304A1 (fr) * 2023-02-24 2024-08-29 Alterome Therapeutics, Inc. Modulateurs de kras
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
CR20250413A (es) * 2023-04-05 2025-11-06 Pfizer Compuestos de pirido[4,3–d]pirimidina
WO2024218686A1 (fr) * 2023-04-20 2024-10-24 Pfizer Inc. Composés pyrido[4,3-d]pyrimidine
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121194980A (zh) * 2023-05-16 2025-12-23 和记黄埔医药(上海)有限公司 三环类化合物及其用途
EP4724445A1 (fr) 2023-06-06 2026-04-15 Kumquat Biosciences Inc. Hétérocycles substitués et leurs utilisations
EP4735451A1 (fr) 2023-06-30 2026-05-06 Kumquat Biosciences Inc. Composés aminés tricycliques condensés substitués et leurs utilisations en tant qu'inhibiteurs de ras
WO2025006967A1 (fr) 2023-06-30 2025-01-02 Bristol-Myers Squibb Company Inhibiteurs de kras
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20260096846A (ko) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Kras 단백질의 소분자 억제제
AU2024404270A1 (en) * 2023-12-19 2026-07-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Fused tricyclic compound and medical use thereof
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
TW202608896A (zh) * 2024-04-30 2026-03-01 大陸商和記黃埔醫藥(上海)有限公司 抗體藥物偶聯物及其用途
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026035945A1 (fr) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Conjugués médicamenteux induits par covalence ciblant kras et comprenant une charge utile de topoisomérase
TW202615038A (zh) 2024-08-07 2026-04-16 美商太斯萊特醫藥美國有限責任公司 包含拓樸異構酶有效載荷之靶向kras之共價誘導之藥物結合物
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026064520A1 (fr) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Conjugués médicamenteux à induction covalente ciblant kras et comprenant une charge utile inhibitrice de tubuline
WO2026064527A1 (fr) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Conjugués médicamenteux à induction covalente ciblant kras comprenant une charge utile d'inhibiteur de tubuline
WO2026072904A2 (fr) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions et méthodes de traitement du cancer du poumon
WO2026090116A2 (fr) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Inhibiteurs de ras
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (fr) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Utilisation d'inhibiteurs ras pour traiter un cancer
WO2026106912A1 (fr) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026112260A1 (fr) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026122764A2 (fr) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026128688A2 (fr) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026161839A1 (fr) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Inhibiteurs de ras
CN119874616B (zh) * 2025-03-28 2025-05-30 四川美域高生物医药科技有限公司 一种有机中间体及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
SI2242771T1 (sl) 2007-12-14 2013-09-30 Bristol-Myers Squibb Company Vezane molekule k humanemu ox40 receptorju
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
EP2760857A1 (fr) 2011-09-27 2014-08-06 F.Hoffmann-La Roche Ag Composés de type pyrazol-4-yl-hétérocyclyl-carboxamide et leurs méthodes d'utilisation
EP2780039B9 (fr) 2011-11-17 2018-04-18 Pfizer Inc Peptides cytotoxiques et conjugués anticorps-médicaments de ceux-ci
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
HUE057285T2 (hu) 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
WO2017175156A1 (fr) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Amides hétérocycliques utiles en tant que modulateurs de protéine
SG10201900628RA (en) 2016-04-07 2019-02-27 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
US11589667B2 (en) 2016-11-16 2023-02-28 Wink Robotics Deformable end effectors for cosmetic robotics
WO2018206539A1 (fr) * 2017-05-11 2018-11-15 Astrazeneca Ab Composés hétéroaryle inhibant des protéines ras portant la mutation g12c
CN111148762A (zh) 2017-05-31 2020-05-12 斯特库伯株式会社 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途
JP7234142B2 (ja) 2017-06-02 2023-03-07 ファイザー・インク Flt3に特異的な抗体およびその使用
MA49772A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Agonistes benzo[b]thiophène de sting pour le traitement du cancer
EP3964516A4 (fr) * 2019-04-28 2023-01-11 Genfleet Therapeutics (Shanghai) Inc. Composé oxaazaquinazoline-7(8h)-cétone, son procédé de préparation et son application pharmaceutique
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
CN113980032B (zh) * 2020-07-27 2023-06-16 江苏恒瑞医药股份有限公司 稠合四环类衍生物、其制备方法及其在医药上的应用
EP4262807A4 (fr) * 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Inhibiteurs pan-kras d'azaquinazoline
CN117083281A (zh) * 2021-03-24 2023-11-17 南京明德新药研发有限公司 嘧啶并杂环类化合物及其应用
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
CN118019746A (zh) * 2021-09-27 2024-05-10 北京加科思新药研发有限公司 多环稠环衍生物及其用途

Also Published As

Publication number Publication date
TW202409047A (zh) 2024-03-01
CA3261000A1 (fr) 2024-01-11
AU2023302139A1 (en) 2024-12-19
TWI869913B (zh) 2025-01-11
MX2024015001A (es) 2025-01-09
CO2024016875A2 (es) 2024-12-19
PY2352053A (es) 2025-03-06
TW202513571A (zh) 2025-04-01
KR20250029954A (ko) 2025-03-05
EP4551296A1 (fr) 2025-05-14
CL2024003699A1 (es) 2025-04-11
JP2025525406A (ja) 2025-08-05
IL317957A (en) 2025-02-01
CR20240556A (es) 2025-01-29
CN119585286A (zh) 2025-03-07
DOP2024000275A (es) 2025-01-31
PE20250259A1 (es) 2025-01-29
WO2024009191A1 (fr) 2024-01-11

Similar Documents

Publication Publication Date Title
EP3980010A4 (fr) Composés de pyrazolo[1,5-a]pyrimidine 2,3,5-trisubstitués
CA3261000A1 (fr) Composés pyrido[4,3-d]pyrimidines
DK4139309T5 (da) [1,3]diazino[5,4-d]pyrimidiner som her2-inhibitorer
IL289456A (en) Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds
FR24C1046I2 (fr) Derives pyrrolo [2,3-d] pyrimidine comme inhibiteurs de la proteine kinase b
MA53675A (fr) Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret
MA53487A (fr) Composés pyrazolo[3,4-b]pyridine utilisés en tant qu'inhibiteurs de kinases tam et met
PT1235830E (pt) Compostos de pirrolo¬2,3-d|pirimidina como inibidores das proteina cinases
BRPI0809998A2 (pt) Composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina cinase
CY1110933T1 (el) 5,7-διαμινοπυραζολο[4,3-d]πυριμιδινες με ανασταλτικη της pde-5 δραστικοτητα
EP3744723A4 (fr) Composé macrocyclique de pyrazolo [1,5-a]pyrimidine substitué
DK3611174T3 (da) [1,2,4]triazolo[1,5-c]pyrimidinderivat som a2a-receptorinhibitor
IL282740B2 (en) 4-Tetrahydropyran-4-yl-6-fluoro-7-phenyl-8,7,6,5-tetrahydro-H1-pyrido[3,2-d]pyrimidine-2,4-dione
IL312020A (en) Imidazo[1,2-a]pyridine derivatives
DK1697356T3 (da) Pyrido[2,3-d]pyrimidin-2,4-diaminer som PDE 2-inhibitorer
EP2276346A4 (fr) Composés de pyrimidine bicycliques fusionnés en tant qu'inhibiteurs d'aurora kinase
DK1797099T3 (da) Piperidinylamino-thieno[2,3-D]pyrimidinforbindelser
PT3184526T (pt) Derivados de pirrolo[2,3-d]pirimidina como inibidores da cinase janus
EP4446323A4 (fr) Composé de pyridine[4,3-d]pyrimidine utilisé en tant qu'agoniste du tlr7/8
DK3483163T3 (da) Triazolo[4,5-d]pyrimidinderivater som cb2-receptorantagonister
EP4512801A4 (fr) Composé 3,4-dihydroquinolin-2(1h)-one
DK4247813T3 (da) Fremgangsmåde til fremstilling af 7-chlor-6-fluor-1-(2-isopropyl-4-methylpyridin-3- yl)pyridof[2,3-d]pyrimidin-2,4(1 h,3 h)-dion
EP3096762C0 (fr) Pyrazolo[1,5-a]pyrimidines comme composés antiviraux
MA46690A (fr) Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
ATE516291T1 (de) Thenopyrimidin-verbindungen mit fungizider aktivität